Flagship Pioneering, LLC Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001400240

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidFocusedHealth TiltBuy & Hold how tags are computed

Q3 2026 · 5 positions · Total reported value $1.96B · Top-10 concentration 100.0% · Updated 2026-11-17

Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR

Turnover: 0.0% · 0 new · 0 cut · 0 exited

Active Share (vs S&P 500): 99.9% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

In its Q3 2026 13F filing, Flagship Pioneering, LLC disclosed 5 equity positions with a combined reported value of $1.96B. The filing implies a focused portfolio: its ten largest positions account for 100.0% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / Buy & Hold.

The largest disclosed positions as of Q3 2026 were GENB ($941.35M), MRNA ($892.01M), SANA ($72.88M). By sector, the heaviest allocations are Health Care 100.0%.

Versus the prior quarter, Flagship Pioneering, LLC opened 0 new positions, trimmed 0 and fully exited 0, a turnover rate of 0.0% of positions. The portfolio's overlap with the prior quarter was 100% of names.

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

Insider Transactions (Form 4)

Latest Flagship Pioneering, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Flagship Pioneering, LLC is an SEC-registered 13F filer. As of Q3 2026 it reported 5 US equity positions with a combined value of $1.96B. HoldingsHub carries 13 quarters of its filings (Q3 2023–Q3 2026).

Portfolio Structure

  • 5 positions · $1.96B reported value (Q3 2026)
  • Top 10 holdings = 100.0% of reported value
  • Largest position: GENB (GENERATE BIOMEDICINES INC) at 48.1%
  • Average position size: $391.07M

Sector Tilt

  • Health Care 100.0%
  • (classified holdings cover 100% of value)

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall direction and market view: The fund maintained a concentrated, bullish stance on biotech/Health Care, with no new additions. The sharp increase in Moderna’s weight (21.07% → 45.62%) suggests a strong positive view on mRNA therapeutics, while trimming positions in Generate Biomedicines (68.66% → 48.14%) indicates profit-taking or rebalancing. 2. Key moves: No additions (0 new positions). Reduced: Generate Biomedicines (weight -20.52pp), Sana Biotechnology (-1.94pp), Foghorn Therapeutics (-1.71pp), and Seres Therapeutics (-0.39pp). Moderna’s weight rose significantly (+24.55pp) due to price appreciation (no share change). 3. Portfolio structure: Highly active, concentrated (5 holdings), and sector-specific (100% Health Care). High risk appetite, with >90% in two volatile biotech stocks (GENB, MRNA). 4. Per-holding one-liner: - GENB: Generate Biomedicines (AI-driven protein design, Health Care). - MRNA: Moderna (mRNA vaccine/therapeutics, Health Care). - SANA: Sana Biotechnology (cell/gene therapy, Health Care). - FHTX: Foghorn Therapeutics (epigenetics, Health Care). - MCRB: Seres Therapeutics (microbiome therapeutics, Health Care). 5. Style summary: Concentrated biotech fund with aggressive bets on mRNA tech, trimming winners to rebalance amid sector volatility.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice. · AI generated 2026-11-17 10:15

Sector Allocation

Health Care 100.0%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 62.67M $941.35M 48.14%
48.14%
Hold
2 4.63M $892.01M 45.62%
45.62%
Hold
3 25.00M $72.88M 3.73%
3.73%
Hold
4 12.67M $45.25M 2.31%
2.31%
Hold
5 1.16M $3.87M 0.20%
0.20%
Hold

FAQ

What did Flagship Pioneering, LLC buy in 2026-Q3?

In its 2026-Q3 13F filing, Flagship Pioneering, LLC reported 5 equity positions worth $1.96B in aggregate; its largest disclosed positions were GENB ($941.35M), MRNA ($892.01M), SANA ($72.88M).

How large is Flagship Pioneering, LLC's portfolio?

Flagship Pioneering, LLC reported $1.96B of long equity holdings across 5 positions as of 2026-Q3. Top-10 holdings account for 100.0% of reported value.

What is Flagship Pioneering, LLC's investment style?

HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / Buy & Hold, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/flagship-pioneering/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →